安杰思(688581) - 杭州安杰思医学科技股份有限公司2024年10月投资者关系记录表

Financial Performance - The company's main business revenue for the first three quarters of 2023 reached 427 million CNY, representing a year-over-year increase of 23.50% [2] - Net profit attributable to shareholders was 197 million CNY, up 37.91% year-over-year [2] - The company's net profit after deducting non-recurring gains and losses was 192 million CNY, reflecting a 36.52% increase [2] - Earnings per share stood at 2.45 CNY, marking a 19.38% rise [2] Sales Breakdown - Domestic sales revenue amounted to 203 million CNY, with a year-over-year growth of 14.44% [3] - Overseas sales revenue reached 222 million CNY, showing a significant increase of 33.20% [3] - The overall product gross margin was 72.23%, an increase of 2.71 percentage points compared to the same period last year [3] Research and Development - The proportion of R&D personnel in the company reached 22.18%, an increase of 6 percentage points year-over-year [3] - The percentage of R&D staff with master's degrees or higher was 34.55%, up 18.38 percentage points from the previous year [3] - The company has obtained 10 new registration certificates for its products this year [5] Market Expansion - The North American market grew by 48.28%, the Asia-Pacific market by 81.93%, and the South American market by 42.69% from January to September 2024 [4] - The company is establishing a factory in Thailand, expected to commence production and sales by Q2 2025, and is also looking for suitable targets in the US and Europe for potential acquisitions or restructuring [3] Industry Outlook - Despite current challenges in the Chinese economy and healthcare sector, the future remains optimistic due to aging population and increasing medical demands [6] - The market is expected to normalize as policy directions become clearer [6]